Search Medical Condition
Please enter condition
Please choose location

Fort gordan, Georgia Clinical Trials

A listing of Fort gordan, Georgia clinical trials actively recruiting patient volunteers.

RESULTS

Found (47) clinical trials

Entyvio (Vedolizumab) Long Term Safety Study

The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 ...

Phase N/A

1.09 miles

Learn More »

S0820 Adenoma and Second Primary Prevention Trial

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main ...

Phase

1.37 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction of anemia and maintenance of Hb in subjects with anemia secondary to CKD who have recently initiated dialysis treatment for end-stage renal disease.

Phase

2.91 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD

Phase

2.91 miles

Learn More »

Anti-VEGF Treatment for Prevention of PDR/DME

Multiple studies have implicated vascular endothelial growth factor VEGF as a major causative factor in human eye diseases characterized by neovascularization including proliferative diabetic retinopathy (PDR) and vascular permeability including diabetic macular edema (DME). While there is strong evidence that PDR outcomes are markedly reduced in eyes that are treated ...

Phase

5.73 miles

Learn More »

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee Hip or Shoulder Replacement

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

Phase

5.73 miles

Learn More »

Safety Study of IgAN LN MN & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

This is a Phase 2, multicenter study of OMS721 in subjects with the following diseases: IgA Nephropathy (IgAN), Lupus Nephritis, Membranous Nephropathy (MN), or C3 Glomerulopathy, including Dense Deposit Disease. Two cohorts will be enrolled. Cohort 1 will be subjects with corticosteroid dependent IgAN, LN, MN, or C3 Glomerulopathy. Cohort ...

Phase

5.73 miles

Learn More »

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who ...

Phase

5.73 miles

Learn More »

Treatment for CI-DME in Eyes With Very Good VA Study

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent ...

Phase

5.73 miles

Learn More »

STP206 for the Prevention of NEC

The study will be conducted in two parts. Part A will be a sequential dose escalation study to determine the safety and tolerability of two doses of STP206 versus control. Part B will evaluate safety and NEC preventive efficacy of STP206 in VLBW and ELBW neonates.

Phase

5.73 miles

Learn More »